Skip to main content
Clinical Trials/NCT01669317
NCT01669317
Completed
Not Applicable

Mechanisms Underlying the Sleep Promoting Effect of Cherry Juice Standardized to Its Proanthocyanidin Content

Pennington Biomedical Research Center1 site in 1 country10 target enrollmentJune 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Insomnia
Sponsor
Pennington Biomedical Research Center
Enrollment
10
Locations
1
Primary Endpoint
Compare the polysomnography of participants with insomnia
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This study is designed to demonstrate that cherry juice is effective in treating insomnia, and to show that it works by inhibiting an enzyme that will be measured in the blood.

Detailed Description

This study will consist of 4 visits - 1 screening visit and 3 treatment visits. Screening visit will consist of a fasting chemistry panel, a health questionnaire, an Insomnia Severity Index, the Epworth Sleepiness Scale, the Pittsburgh Sleep Quality Index, the Beck Depression Inventory, the State-Trait Anxiety Inventory, and the Fatigue Severity Scale. Ten subjects passing screening will take for 2 weeks between dinner and bedtime in a blinded and balanced order: 1. Eight ounces of cherry juice standardized to its proanthocyanidin content in the morning and 8 ounces of cherry juice standardized to its procyanidin content 1-2 hours before bedtime for 14 days; 2. A similar amount of placebo juice with the same timing for the cross-over. There will be a 2-week washout between each of the treatment periods. Subjects will be scheduled for two overnight PSGs, one at the end of each two-week treatment period. On the morning following each test the insomnia severity index and other questionnaires will be repeated. The order of the placebo juice and cherry juice will be random and balanced.

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
October 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Frank Greenway

Principal Investigator

Pennington Biomedical Research Center

Eligibility Criteria

Inclusion Criteria

  • Healthy male or female with a usual bedtime between 9 pm and midnight.
  • 65 years of age or older.
  • Sleep problem \>3 nights per week, meeting the International Classification of Sleep Disorders (ICSD-2\*) diagnostic criteria of insomnia for at least 6 months.
  • An insomnia severity index ≥ 10 and a minimum of 30 minutes of either sleep-onset latency (SL) or wake after sleep onset (WASO).
  • \*ICSD-2 general criteria for insomnia:
  • A complaint of difficulty initiating sleep, difficulty maintaining sleep, or waking up too early, or sleep that is chronically non-restorative or poor in quality.
  • The above sleep difficulty occurs despite adequate opportunity and circumstances for sleep.
  • At least one of the following forms of daytime impairment related to the nighttime sleep difficulty is reported by the patient:
  • Fatigue or malaise.
  • Attention, concentration, or memory impairment.

Exclusion Criteria

  • Diabetes.
  • Sedating or hypnotic medications.
  • Any chronic medication that has not had a stable dose for 1 month or longer.

Outcomes

Primary Outcomes

Compare the polysomnography of participants with insomnia

Time Frame: Baseline and Week 4

Compare the polysomnography of participants with insomnia on a night at the end of 2 weeks taking: Eight ounces of standardized cherry juice vs. the night taking the placebo juice.

Secondary Outcomes

  • Comparison of insomnia sleep scales(Baseline and Week 4)
  • Differences in the enzyme blood test(Baseline, Week 2 & Week 4)
  • Compare the Insomnia Severity Index and validated questionnaires(Baseline and Week 4)

Study Sites (1)

Loading locations...

Similar Trials